Dr. Faiez Zannad is a world-renowned cardiologist and Professor Emeritus of Therapeutics at the Université de Lorraine in France. He earned his medical degree and completed his clinical pharmacology training at Université Claude Bernard in Lyon, with additional research at Oxford's Medical Research Council. Born in Monastir, Tunisia in 1951, he began his academic career at the CHU de Nancy in 1981, where he rose to become a leading figure in cardiovascular medicine. Throughout his distinguished career, he established the Cardiac Insufficiency care network in Lorraine and served as Director of the Inserm Clinical Investigation Centre at the Institut Lorrain du Coeur et des Vaisseaux.
Dr. Zannad has made seminal contributions to the evidence base supporting modern heart failure therapies, particularly in mineralocorticoid receptor antagonists, beta-blockers, and SGLT2 inhibitors, which have significantly improved patient outcomes worldwide. His groundbreaking COMMANDER HF trial, published in the New England Journal of Medicine, involved 5,022 patients across 32 countries and provided critical insights into anticoagulation therapy for heart failure patients. With over 800 peer-reviewed publications, 81,218 citations as of 2016, and an H-index of 85, his research has fundamentally shaped clinical practice guidelines for heart failure management. He has led major European Union-funded initiatives including HOMAGE on omics biomarkers and FIBROTARGETS on fibrosis as a therapeutic target in heart failure.
A visionary leader in cardiovascular research, Dr. Zannad founded the Global CardioVascular Clinical Trialists Forum, fostering international collaboration among clinical trial experts from institutions including the FDA, EMA, and NHLBI. He has held prominent leadership positions as former President of the French Society of Hypertension and the European Society of Cardiology Working Group on Pharmacology and Drug Therapy. His numerous accolades include the European Society of Hypertension Paul Milliez Award, the ESC-Heart Failure Association Lifetime Achievement Award, and the Eugene Braunwald Scholarship from Harvard Medical School. Currently, he continues to advance cardiovascular science through biomarker research, co-founding the Transatlantic Heart Failure Biomarker Working Group and promoting the concept of Cardiac Liver Metabolism through the MOSAIC initiative.
